TY - JOUR
T1 - Chronic kidney disease and incident cancer risk
T2 - an individual participant data meta-analysis
AU - Mok, Yejin
AU - Surapaneni, Aditya
AU - Sang, Yingying
AU - Coresh, Josef
AU - Grams, Morgan E.
AU - Matsushita, Kunihiro
AU - Ballew, Shoshana H.
AU - Alencar de Pinho, Natalia
AU - Ärnlöv, Johan
AU - Barreto, Sandhi M.
AU - Bell, Samira
AU - Brenner, Hermann
AU - Carrero, Juan Jesus
AU - Chinnadurai, Rajkumar
AU - Ciemins, Elizabeth
AU - Gansevoort, Ron T.
AU - Jassal, Simerjot K.
AU - Jung, Keum Ji
AU - Kirchner, H. Lester
AU - Konta, Tsuneo
AU - Kovesdy, Csaba P.
AU - Luo, Li
AU - Pandit, Krutika
AU - Rahman, Mahboob
AU - CKD Prognosis Consortium
AU - Robinson-Cohen, Cassianne
AU - Sabanayagam, Charumathi
AU - Schultheiss, Ulla T.
AU - Shlipak, Michael
AU - Staplin, Natalie
AU - Tonelli, Marcello
AU - Wang, Angela Yee Moon
AU - Wen, Chi Pang
AU - Woodward, Mark
AU - Lees, Jennifer S.
AU - Shlipak, Michael G.
AU - Nitsch, Dorothea
AU - Levey, Andrew S.
AU - Giedraitis, Vilmantas
AU - Larsson, Anders
AU - Lees, Jennifer
AU - Tsai, Min Kung
AU - Ritchie, James
AU - Sinha, Smeeta
AU - Green, Darren
AU - Kalra, Philip
AU - Baigent, Colin
AU - Landray, Martin J.
AU - Herrington, William
AU - Livingstone, Shona
AU - Chalmers, John
N1 - Funding: The CKD Prognosis Consortium (CKD-PC) Data Coordinating Centre is funded in part by a programme grant from the US National Kidney Foundation and the National Institute of Diabetes and Digestive and Kidney Diseases (R01DK100446). A variety of sources have supported enrolment and data collection, including laboratory measurements and follow-up in the collaborating cohorts of the CKD-PC. These funding sources include government agencies such as the National Institutes of Health and Medical Research Councils, as well as foundations and industry sponsors listed in Supplemental Appendix 3. Dr. Lees is personally funded by a Wellcome Trust Early Career Award (301005/Z/23/Z).
PY - 2025/11/30
Y1 - 2025/11/30
N2 - Background: Studies examining the association of chronic kidney disease (CKD) with cancer risk have demonstrated conflicting results. Methods: This was an individual participant data meta-analysis including 54 international cohorts contributing to the CKD Prognosis Consortium. Included cohorts had data on albuminuria [urine albumin-to-creatinine ratio (ACR)], estimated glomerular filtration rate (eGFR), overall and site-specific cancer incidence, and established risk factors for cancer. Included participants were aged 18 years or older, without previous cancer or kidney failure. Results: Among 1,319,308 individuals, the incidence rate of overall cancer was 17.3 per 1000 person-years. Higher ACR was positively associated with cancer risk [adjusted hazard ratio 1.08 (95% CI 1.06–1.10) per 8-fold increase in ACR]. No association of eGFR with overall cancer risk was seen. For site-specific cancers, lower eGFR was associated with urological cancer and multiple myeloma, whereas higher ACR was associated with many cancer types (kidney, head/neck, colorectal, liver, pancreas, bile duct, stomach, larynx, lung, hemolymphatic, leukaemia, and multiple myeloma). Results were similar in a 1-year landmark analysis. Discussion: Albuminuria, but not necessarily eGFR, was independently associated with the subsequent risk of cancer. Our results warrant an investigation into mechanisms that explain the link between albuminuria and cancer.
AB - Background: Studies examining the association of chronic kidney disease (CKD) with cancer risk have demonstrated conflicting results. Methods: This was an individual participant data meta-analysis including 54 international cohorts contributing to the CKD Prognosis Consortium. Included cohorts had data on albuminuria [urine albumin-to-creatinine ratio (ACR)], estimated glomerular filtration rate (eGFR), overall and site-specific cancer incidence, and established risk factors for cancer. Included participants were aged 18 years or older, without previous cancer or kidney failure. Results: Among 1,319,308 individuals, the incidence rate of overall cancer was 17.3 per 1000 person-years. Higher ACR was positively associated with cancer risk [adjusted hazard ratio 1.08 (95% CI 1.06–1.10) per 8-fold increase in ACR]. No association of eGFR with overall cancer risk was seen. For site-specific cancers, lower eGFR was associated with urological cancer and multiple myeloma, whereas higher ACR was associated with many cancer types (kidney, head/neck, colorectal, liver, pancreas, bile duct, stomach, larynx, lung, hemolymphatic, leukaemia, and multiple myeloma). Results were similar in a 1-year landmark analysis. Discussion: Albuminuria, but not necessarily eGFR, was independently associated with the subsequent risk of cancer. Our results warrant an investigation into mechanisms that explain the link between albuminuria and cancer.
UR - https://www.scopus.com/pages/publications/105021352805
U2 - 10.1038/s41416-025-03140-z
DO - 10.1038/s41416-025-03140-z
M3 - Article
C2 - 40914744
AN - SCOPUS:105021352805
SN - 0007-0920
VL - 133
SP - 1535
EP - 1543
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 10
ER -
SDG 3 Good Health and Well-being